Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$82,986.00+1.18%ETH$2,456.32+2.08%GOLD$4,149.30+0.16%OIL$98.02+0.20%
Smart Investors Daily
SID Premium
PR

NASDAQ · PROK

ProKidney Corp.

Healthcare · Biotechnology

$1.40

Up+$0.05 (+3.23%)

Updated Oct 20, 2026, 10:39 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
623.32M
P/E ratio
-4
Dividend yield
0.00%
52-week range
$1.30 – $3.48
Volume
966.87K
Avg. volume
1.98M

Price performance · PROK

PROK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 19, 2026

PROK closed at $1.40 after 21 trading sessions, down 21.41% for the selected period.

Last close
$1.40
Period change
-21.41%
Period low
$1.33
Period high
$1.83
Daily close
View OHLC price history
PROK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 19, 2026$1.35$1.41$1.35$1.395966.87K
Oct 16, 2026$1.43$1.4744$1.305$1.331.67M
Oct 15, 2026$1.44$1.485$1.42$1.4551.11M
Oct 14, 2026$1.54$1.57$1.41$1.472.13M
Oct 13, 2026$1.65$1.68$1.53$1.571.6M
Oct 12, 2026$1.71$1.74$1.66$1.67607.84K
Oct 9, 2026$1.65$1.75$1.635$1.741.39M
Oct 8, 2026$1.55$1.67$1.53$1.661.13M
Oct 7, 2026$1.56$1.60$1.55$1.57832.19K
Oct 6, 2026$1.58$1.61$1.555$1.60771.31K
Oct 5, 2026$1.69$1.735$1.58$1.58985.94K
Oct 2, 2026$1.72$1.745$1.66$1.721.09M
Oct 1, 2026$1.66$1.76$1.635$1.711.51M
Sep 30, 2026$1.65$1.675$1.60$1.661.2M
Sep 29, 2026$1.61$1.68$1.605$1.631M
Sep 28, 2026$1.58$1.64$1.54$1.611.81M
Sep 25, 2026$1.67$1.69$1.565$1.602.17M
Sep 24, 2026$1.65$1.6891$1.60$1.681.73M
Sep 23, 2026$1.81$1.84$1.65$1.651.44M
Sep 22, 2026$1.78$1.86$1.772$1.83588.52K
Sep 21, 2026$1.90$1.9094$1.715$1.7751.77M

Latest PROK news

The latest Smart Investors Daily articles mentioning PROK.

Stock researchCompany · Overview

PROK research

Overview

Company profile and research snapshot.

Company profile

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.67
Implied upside
—
Analysts
—
PROK recent ratings
DateFirmRatingTarget
May 18, 2026HC Wainwright & Co.Buy—
Dec 16, 2025HC Wainwright & Co.Buy—
Jul 15, 2025UBSBuy—
Jul 14, 2025GuggenheimBuy—
Jul 9, 2025CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencelOne clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKid

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By